- Genetic disorders of glycine metabolism are inherited conditions caused by changes in genes that regulate glycine synthesis, degradation, transport, utilization, or related metabolic pathways. Because glycine participates in protein synthesis, one-carbon metabolism, nucleotide production, heme biosynthesis, glutathione synthesis, neurotransmission, and mitochondrial metabolism, genetic abnormalities affecting glycine-related proteins can have effects across multiple biological systems. These disorders can range from rare metabolic diseases caused by defects in the glycine cleavage system to neurological conditions involving glycine transport or receptor function.
- One of the best-known inherited disorders associated with glycine metabolism is nonketotic hyperglycinemia (NKH), also called glycine encephalopathy. It is primarily caused by impaired activity of the mitochondrial glycine cleavage system, which normally degrades glycine and transfers a one-carbon unit into the folate pathway. When glycine cleavage is impaired, glycine can accumulate in body fluids, including the central nervous system. The resulting biochemical disturbance can be associated with severe neurological manifestations.
- Several genes can cause nonketotic hyperglycinemia because the glycine cleavage system consists of multiple protein components. Important genes include GLDC, AMT, and GCSH, while pathogenic variants affecting DLD can also interfere with glycine cleavage activity. GLDC encodes the P protein, AMT encodes the T protein, GCSH encodes the H protein, and DLD encodes the L protein. Because these proteins work together as a mitochondrial enzyme system, disruption of any essential component can reduce glycine degradation.
- The GLDC gene is one of the major genetic causes of nonketotic hyperglycinemia. It encodes glycine dehydrogenase, the P protein of the glycine cleavage system. The enzyme initiates glycine breakdown by removing carbon dioxide from glycine and transferring the remaining aminomethyl group to the H protein. Variants that substantially reduce GLDC function can therefore cause glycine accumulation and disruption of glycine-dependent metabolic pathways.
- The AMT gene encodes aminomethyltransferase, the T protein of the glycine cleavage system. This component transfers the aminomethyl group from the H protein to tetrahydrofolate, generating 5,10-methylene-tetrahydrofolate. AMT deficiency therefore affects both glycine degradation and one-carbon metabolism. Genetic variants in AMT are another important cause of nonketotic hyperglycinemia.
- The GCSH gene encodes the H protein, which acts as a carrier within the glycine cleavage system. Its lipoylated domain allows reaction intermediates to move between the different components of the complex. Changes affecting GCSH can therefore interfere with coordinated glycine degradation. The clinical and biochemical consequences depend on the specific genetic variant and its effect on protein function.
- The DLD gene encodes dihydrolipoamide dehydrogenase, the L protein of the glycine cleavage system. DLD is particularly interesting because the same enzyme also participates in other mitochondrial dehydrogenase complexes. Consequently, pathogenic DLD variants may produce biochemical abnormalities that extend beyond glycine metabolism. This illustrates why genetic disorders involving mitochondrial metabolic proteins can have broad metabolic effects.
- The biochemical hallmark of impaired glycine cleavage is an elevation of glycine, often particularly evident in the cerebrospinal fluid (CSF). Measurement of glycine in plasma and CSF can therefore contribute to the biochemical evaluation of suspected nonketotic hyperglycinemia. The relationship between plasma and CSF glycine concentrations can provide useful diagnostic information, although biochemical testing is generally interpreted together with clinical findings and genetic analysis.
- Because glycine functions as both an inhibitory neurotransmitter and an NMDA receptor co-agonist, excessive glycine in the central nervous system can affect neuronal signaling. Glycine activates glycine receptors, which are ligand-gated chloride channels involved in inhibitory neurotransmission, while it also participates as a co-agonist at NMDA receptors. The neurological manifestations of disorders affecting glycine metabolism therefore reflect not only metabolic imbalance but also disturbances in neurotransmitter signaling.
- Nonketotic hyperglycinemia can present at different ages and with different degrees of severity. Severe early-onset forms may become apparent during the neonatal period, whereas other forms can present later with neurological or developmental abnormalities. Clinical features can include abnormalities in muscle tone, seizures, altered consciousness, developmental impairment, movement abnormalities, and other neurological findings. The specific presentation varies according to the underlying genetic and biochemical defect.
- Genetic disorders can also affect glycine metabolism indirectly by altering glycine transport. The genes SLC6A9 and SLC6A5 encode GlyT1 and GlyT2, respectively. These transporters regulate glycine movement across cell membranes and have important functions in the nervous system. Variants affecting glycine transport can alter extracellular glycine concentrations or interfere with glycinergic neurotransmission, demonstrating that genetic disorders of glycine biology are not limited to defects in metabolic enzymes.
- SLC6A5, which encodes GlyT2, has particular importance in glycinergic neurons. GlyT2 contributes to the recovery and recycling of glycine following neurotransmitter release. Pathogenic variants in SLC6A5 have been associated with neurological disorders involving impaired glycinergic neurotransmission, including forms of hyperekplexia, a disorder characterized by exaggerated startle responses and other abnormalities of inhibitory neurotransmission.
- Glycine receptor genes can also be involved in inherited neurological disorders. The GLRA1 gene encodes the alpha-1 subunit of the glycine receptor and is an important gene in hereditary hyperekplexia. Other glycine receptor subunit genes, including GLRB, can also contribute to disorders affecting glycinergic signaling. These conditions demonstrate the importance of distinguishing between defects in glycine metabolism, glycine transport, and glycine receptor function.
- Genetic disorders affecting glycine metabolism can also arise from abnormalities in pathways connected to glycine rather than from defects in glycine-specific enzymes. Glycine participates in serine metabolism, folate metabolism, one-carbon metabolism, purine nucleotide synthesis, heme biosynthesis, and glutathione synthesis. Variants in genes controlling these pathways can therefore indirectly influence glycine availability, utilization, or metabolic flux.
- The enzymes SHMT1 and SHMT2 provide an important example of this metabolic integration. SHMT1 and SHMT2 catalyze the reversible conversion of serine and glycine while transferring one-carbon units to tetrahydrofolate. Changes in these pathways can influence glycine-serine balance and one-carbon metabolism. Their biological importance is particularly evident in cells with high requirements for nucleotide synthesis and other biosynthetic processes.
- Genetic abnormalities can also affect glycine homeostasis through changes in mitochondrial function. Much of glycine degradation occurs within mitochondria through the glycine cleavage system, while mitochondrial serine-glycine metabolism contributes to one-carbon metabolism. Consequently, inherited mitochondrial disorders or defects in mitochondrial enzymes can alter glycine concentrations and metabolic flux even when glycine itself is not the primary metabolic target.
- The consequences of genetic defects can depend strongly on the type of variant. Missense variants replace one amino acid in a protein with another and may alter enzyme activity, protein folding, stability, or interactions with other proteins. Nonsense variants can introduce premature stop signals, while insertions, deletions, splice-site variants, and larger genomic changes can affect protein production or RNA processing. Understanding the molecular effect of a variant is therefore important when interpreting genetic test results.
- Modern genetic variant interpretation combines DNA sequencing with biochemical, computational, and functional evidence. Whole-exome sequencing and whole-genome sequencing can identify variants in genes associated with glycine metabolism, while targeted sequencing can be used when a particular disorder is suspected. Bioinformatics tools can help evaluate variant frequency, predicted protein effects, conservation, gene function, and known disease associations.
- Functional studies provide another level of evidence. Enzyme activity measurements, protein-expression experiments, cellular assays, metabolic profiling, and other laboratory approaches can help determine whether a genetic variant changes biological function. For disorders such as nonketotic hyperglycinemia, genetic information can be particularly informative when combined with measurements of glycine concentrations and other biochemical markers.
- Metabolomics can also contribute to the investigation of genetic disorders of glycine metabolism. Changes in glycine, serine, one-carbon metabolites, organic acids, nucleotides, and other metabolites can provide information about altered metabolic pathways. Stable-isotope tracing can further help determine how carbon atoms move through glycine-serine metabolism, the glycine cleavage system, nucleotide synthesis, and related pathways.
- The study of genetic disorders of glycine metabolism is also important for understanding genotype-phenotype relationships. Different variants within the same gene can produce different effects depending on their influence on protein activity, expression, localization, or stability. Similarly, environmental factors, developmental stage, metabolic state, and additional genetic variants can influence the resulting phenotype. Therefore, the relationship between a genetic variant and clinical presentation is not always simple.
- Glycine-related genetic disorders also illustrate the importance of systems biology. Glycine is connected to many metabolic and cellular pathways, so a defect in one component can influence several biological processes simultaneously. Network analysis can be used to examine relationships between genes, proteins, metabolites, transport systems, and signaling pathways. This approach can provide a broader understanding of how genetic changes affect cellular physiology.
- The nervous system is particularly sensitive to abnormalities in glycine biology because glycine participates directly in neurotransmission. Disorders involving glycine degradation, transport, or receptor activity can therefore produce neurological manifestations even when the primary molecular defect occurs in a metabolic enzyme. The relationship between glycine metabolism and neurotransmission is an important example of how metabolic pathways and cellular signaling systems are interconnected.
- Research into genetic disorders of glycine metabolism also contributes to the development of new diagnostic and therapeutic approaches. Improved DNA sequencing, biochemical testing, metabolomics, and computational variant analysis can help identify affected individuals and clarify molecular mechanisms. Experimental research can investigate how restoring enzyme activity, modifying metabolic pathways, or altering neurotransmitter transport and signaling might influence disease biology.
- Overall, genetic disorders of glycine metabolism include a diverse group of conditions involving glycine degradation, transport, receptor signaling, and interconnected metabolic pathways. The glycine cleavage system genes GLDC, AMT, GCSH, and DLD are central to the study of nonketotic hyperglycinemia, while SLC6A9, SLC6A5, GLRA1, and other glycine-related genes are important for glycine transport and neurotransmission.
